Cantor Fitzgerald’s Post

Are you attending RESI Boston next week? If so, join Portal and Radyus Research for a panel discussion with our Director of Lab and Scientific Operations, Krisha Panchalingam! This panel will discuss maximizing pre-clinical development success for VC-backed startups through CRO partnerships. Additional information is below, and we hope to see you there!

Today on the Business of Biotech, molecular biologist-turned-Chief Business Officer Neela Patel and academic-turned-founder of newly-formed Bonum Therapeutics John Mulligan, Ph.D. pull back the curtain on Bonum's transition from its predecessor, Good Therapeutics, Inc., which was fueled by a high-profile asset sale to Roche. Listen in as Neela and John share how the deal got done, how Good turned to Bonum, and where the company's taking its platform next. Listen and subscribe here: https://lnkd.in/edtyEWsF

🏥 Akiram Therapeutics: The transition from lab to market We are happy to see Akiram Therapeutics, one of our portfolio companies, featured in Life Science Sweden. The article explores the significant journey undertaken by Marika Nestor, CEO at Akiram, along with her team, who navigated the path from academia at Uppsala University to an established biotech company. This transition, which involved translating research into a viable commercial entity, underscores the challenges and triumphs of moving from lab bench to patient bedside. With Akiram, we see the critical steps of securing funding and navigating patent landscapes to produce novel treatments for clinical trials. Find the full feature (in Swedish) here: https://lnkd.in/dYtCZqtw At Sciety, this is what we do. We invest in life science and health tech companies like Akiram, that have the potential to make a real difference in people's lives. We are a long-term partner supporting the growth of our portfolio companies, whether it be through introductions to potential customers, partners and team members, or operational and strategic advice. Want to learn more about how we work and what we invest in? Visit our website: https://lnkd.in/dQMctGqm #Sciety #VentureCapital #LifeScience

In June, our #London team hosted the 2nd meeting of the UK Biotech Club, inviting leaders from 15 #biotech companies in the #Cambridge area. Attendees discussed challenges, opportunities, & best practices. Topics included determining vision & direction, relationship building, extending the runway, and go-to-market strategies. In this paper, we share insights from these discussions & draw out the key takeaways. >> https://lnkd.in/grTbZ6i8

Uncover the Secrets of Biotech IT Evolution: Dive into the 'Calculus of IT' with Nathan McBride of Xilio Therapeutics, Inc. As the biotech industry surges forward, it is imperative to grasp the fundamental elements that define success. From do's and don'ts that can make or break a biotech's journey to finely-tuned launchpad strategies tailored for emerging players in the field, Nate delves into it all in our on-demand video. Watch the whole video here: bit.ly/44oJkq8 For more videos from our Life Sciences Summit, visit: bit.ly/3QwcFeU #LifeSciences #Biotech #ClinicalTrials

Join Laia Pascual Ponce (Ship2B Ventures), Fabrizio Conicella (Chiesi USA, Inc.), Salvatore Cappadona (Criteria Bio Ventures), Anna Bellmunt (Asabys Partners), Kerstin Papenfuss, PhD MBA, (Deep Science Ventures) and Alejo Chorny, (AdBio partners) at RESI Europe 2024, June 17-19, a hybrid conference, in-person (June 17), and online partnering (June 18-19), for the Early Stage Therapeutics Panel. The moderator will guide the discussion through topics including how the investors source and vet novel therapeutic assets, what kinds of technology are of interest to them right now, and how they as investors work with a startup to move a new drug toward commercialization. Register: https://lnkd.in/dhxge-zb #RESI #RESIEUROPE #RESIBARCELONA Biocat, BioRegion of Catalonia Biotechgate

With registration in full swing, we want to take a moment to highlight our case company and key sponsors! We will be showcasing each company throughout the registration period, so follow to learn more about these amazing organizations. As a reminder, case teams must complete an application here by Nov. 27 to register! Application here: https://lnkd.in/eyv49w3d Today, we are highlighting our case company, Orange Grove Bio ! Orange Grove Bio’s mission is to positively transform the quality of life of patients with cancer, autoimmune, and inflammatory diseases, by expediting the development of new medical breakthroughs. They strive to foster a more patient-centric approach to drug development and curative therapies through a collaborative ecosystem that bridges early-stage research and pharmaceutical companies. Orange Grove Bio’s Chief Executive Officer and Co-Founder, Marc Appel was an entrepreneur-in-residence at Yale University. In this role, Marc drove the initiative that propelled university intellectual property into the hands of startups to further fuel the New Haven innovation ecosystem. Orange Grove Bio focuses on geographies outside prime venture capital hubs, including the Southeast, Midwest, and Mid-Atlantic. Sourcing throughout these regions aids in accelerating drug development of valuable therapeutics that receive billions of dollars in annual NIH funding, which are more distant from traditional venture capital regions. #innovation #biotech #YHSI2024 #casecompetition

Can it be Done? Making Life Sciences Start-up Transactions Easier and Faster Workshop at #LESAM23!   Get the latest template agreement that could speed up negotiations between universities and investors in this informative workshop. Speakers: Katharine Ku (Wilson Sonsini), Rick Brandon (University of Michigan), Galya Blachman (Enliven Therapeutics), Miranda Biven (Wilson Sonsini Goodrich & Rosati)

Given the current trajectory of the biotech sector, how prepared are you to ensure the continuity and integrity of your CMC development plan? Remember, it's a critical link in the value chain—can you afford to let it lapse? Reach out for a consultation and be sure to remain on track.

#SwissBiotechDay #AkcesoAdvisors #AndrásIncze Join us at the Swiss Biotech Day next Monday and Tuesday, where our Founder & CEO, Andras Incze, will be serving as a jury member on two pitching sessions! 🎉   The Swiss Biotech Day, hosted by the Swiss Biotech Association, is one of Europe's premier biotechnology conferences, bringing together 2,000 professionals from the global life sciences community.   We are very much looking forward to explore how we at Akceso Advisors could help participating biotechs make sure they maximize the value of their asset. This, by helping them reaching target price for the target patient population, thus maximizing net revenue in an ever-more-challenging pharma landscape.   See you there! ✍ Find the registration link in the first comment.